Pierroz, Dominique D <br/><br/>
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.  [electronic resource] 

 -  The Journal of biological chemistry  Sep 2010 
 - 28164-73 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1083-351X 
<br/><br/><label>Standard No.: </label>10.1074/jbc.M110.101964  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alendronate--administration & dosage<br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Biomarkers--metabolism<br/>Bone Density--drug effects<br/>Bone Resorption--drug therapy<br/>Bone and Bones--cytology<br/>Denosumab<br/>Dose-Response Relationship, Drug<br/>Female<br/>Gene Expression<br/>Gene Knock-In Techniques<br/>Humans<br/>Male<br/>Mice<br/>Osteoclasts--drug effects<br/>Osteogenesis--drug effects<br/>Ovariectomy<br/>Parathyroid Hormone--administration & dosage<br/>RANK Ligand--administration & dosage<br/>Receptor Activator of Nuclear Factor-kappa B--antagonists & inhibitors